Participant baseline demographics, ART history, & clinical characteristics.

ᶲ 1,498 participants enrolled, 1,494 with VL results available.* “suppressed” and “elevated” refers to baseline viral load measurement as below or above the failure threshold of 5,000 copies/ml;† Time on therapy collected on study CRFs but only available for patients enrolled under routine monitoring eligibility. ART time was abstracted from clinic records for all enrolled participants.**267 (59%) on ART for 6 years, 5 (1.1%) for 7 years, 174 (38.6%) for 8 years, and 5 (1.1%) for 10 years.° Symptoms included: Herpes Zoster, popular pruritic eruption, unexplained chronic diarrhea (>1 month), unexplained persistent fever, moderate unexplained weight loss, oral candidiasis, esophageal candidiasis, pulmonary TB, extra-pulmonary TB, pneumonia, Crytpococcal meningitis, Kaposi’s Sarcoma, and Other.‡ Viral load values assigned as midpoint between 0 and lower limit of detection (40 copies/ml for plasma, 550 copies/ml for DBS). Reported values based on per protocol assessment (plasma or vDBS if available). Median and IQR unchanged among suppressed group if using fsDBS only. Median [IQR] based on fsDBS among patients with elevated VL per fsDBS results was 30,870 [17,156–121,306].3TC—Lamivudine; ART—antiretroviral therapy; AZT—Zidovudine; CRF—case report form; d4T —Stavudine; DBS—dried blood spot; EFV—Efavirenz; IQR—interquartile range; NVP—Nevirapine; SD—standard deviation; TB—tuberculosis; TDF—Tenofovir; VL—viral load.Participant baseline demographics, ART history, & clinical characteristics.